Chimerix (NASDAQ:CMRX) Receives Hold Rating from Jefferies Financial Group

Chimerix (NASDAQ:CMRX)‘s stock had its “hold” rating reaffirmed by equities researchers at Jefferies Financial Group in a report released on Wednesday,Benzinga reports. They currently have a $8.50 price target on the biopharmaceutical company’s stock, down from their previous price target of $10.00. Jefferies Financial Group’s target price suggests a potential upside of 0.47% from the company’s current price.

CMRX has been the subject of several other research reports. HC Wainwright reissued a “neutral” rating and issued a $8.55 target price (down previously from $11.00) on shares of Chimerix in a research report on Wednesday. Wedbush reaffirmed a “neutral” rating and issued a $8.55 price target (up from $7.00) on shares of Chimerix in a research note on Wednesday.

Chimerix Price Performance

CMRX stock traded up $3.50 during trading on Wednesday, reaching $8.46. The company had a trading volume of 118,501,179 shares, compared to its average volume of 1,958,944. Chimerix has a 52 week low of $0.75 and a 52 week high of $8.47. The business has a 50 day moving average of $4.04 and a 200 day moving average of $2.17. The company has a market cap of $760.86 million, a P/E ratio of -9.00 and a beta of 0.32.

Insiders Place Their Bets

In other news, CEO Michael T. Andriole sold 7,370 shares of Chimerix stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $4.52, for a total transaction of $33,312.40. Following the completion of the transaction, the chief executive officer now directly owns 609,603 shares in the company, valued at approximately $2,755,405.56. This trade represents a 1.19 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last quarter, insiders have sold 20,760 shares of company stock worth $91,175. 13.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Bender Robert & Associates bought a new position in Chimerix in the 4th quarter worth about $37,000. Susquehanna Fundamental Investments LLC purchased a new stake in shares of Chimerix during the fourth quarter valued at approximately $59,000. Jane Street Group LLC bought a new stake in shares of Chimerix during the fourth quarter valued at approximately $62,000. Diadema Partners LP bought a new stake in shares of Chimerix during the fourth quarter valued at approximately $101,000. Finally, Squarepoint Ops LLC purchased a new position in Chimerix in the 4th quarter worth approximately $130,000. Institutional investors own 45.42% of the company’s stock.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.